Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112993 · ClinicalTrials.gov registry record · Phase 4
Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03112993 is a Phase 4 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 40 participants.
The verdict
NCT03112993, a Phase 4 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Spine surgery is one of the most common operative procedures in the United States. It is performed in the prone position (a patient laying on belly). Muscle relaxants are given for neuromuscular blockade often referred as paralysis for surgical exposure which is maintained until the patient is returned to the supine position (a patient laying on back) at the end of surgery. At the end of the surgery the paralysis is reversed with a drug (neostigmine). A new drug (sugammadex) has the ability to rapidly reverse the paralysis but it is not well investigated in elderly. This study will investigate speed of recovery and complications of the two reversal drugs in elderly patients (age ≥ 65 years) undergoing posterior spine surgery.
Interventions
- DRUG Neostigmine
- DRUG sugammadex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2018-08-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03112993
The ClinicalTrials.gov registry entry for NCT03112993 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Neostigmine is the first listed.
NCT03112993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03112993 about?
NCT03112993 is a clinical study titled "Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery". Spine surgery is one of the most common operative procedures in the United States. It is performed in the prone position (a patient laying on belly). Muscle relaxants are given for neuromuscular blockade often referred as paralysis for surgical exposure which is maintained until the patient is retur...
What is the current status of trial NCT03112993?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2017-05-30. Estimated completion is 2018-08-14.
What interventions are being tested in trial NCT03112993?
The interventions under investigation include: Neostigmine (DRUG), sugammadex (DRUG).
Who is sponsoring clinical trial NCT03112993?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.